CannaLatan is the name of a new initiative, a cannabis network between Spain and Latin America that’s aiming to promote cannabis in both regions. It also aims to raise awareness about the medical properties of this plant by doing research that will allow the development of new drugs. The network involves 10 laboratories and two companies that will join forces in order to push the industry forward.
The Latin American region shares one of the most important cultural principles with Spain: language. Currently, also the cannabis sector serves as a connection to both regions thanks to CannaLatan, the Ibero-American research network on cannabinoids.
This joint cannabis research project, coordinated by the Institute of Neurochemistry of the Complutense University of Madrid will allow the development of new drugs based on molecules found in cannabis and could lead to revolutionary treatments.
The Institute of Neurochemistry of the Complutense University of Madrid will coordinate an unprecedented initiative called “CannaLatan”, a project which involves 10 laboratories and two companies (Plena Global and Emerald Health Biotechnology Spain), from eight countries. The project will allow further research on the therapeutic uses of cannabinoids (the molecules from cannabis).
If you want to know more about cannabis, how Latin America and Spain are working together for the development of the medical cannabis sector, and to find out the latest hemp news, download the Hemp.im mobile application.
CannaLatan will help to promote cannabis in both regions
The new cannabis network will have three main focuses: research, training and dissemination.
Specifically, it will promote the study and development of new cannabis-based drugs for neurodegenerative diseases, such as Alzheimer’s or Parkinson’s, as well as for the control of refractory epilepsy, the type that does not respond to available antiepileptic drugs.
Ismael Galve-Roperh, professor at the UCM and head of this bold project has declared that CannaLatan will also focus on diving deep in order to find the anti-tumor properties of cannabis, which could help to reduce the growth of some types of tumors.
“This is a line of research of which we know a lot at a preclinical level and of which clinical developments are being made,” he added.
According to the researcher, cannabinoids also have effects on neuropsychiatric diseases, such as depression, anxiety, or psychosis. Furthermore, although there is a relationship between THC use in cannabis and some types of psychosis, in diseases such as schizophrenia, the same molecules that induce one thing can induce different responses in other patients.
The network will also promote improved extraction, purification, development and standardization of cannabinoid-based products; in order to increase the quality and safety of potential drugs.
The cannabis network aims to coordinate projects and help to develop new initiatives
One of the network’s objectives is to raise awareness about cannabis, not only in the region but around the world, which would help “to attract additional resources to support research,” explained Galve-Roperh.
Currently, funding for this project is provided by the Ibero-American Program for Science and Technology for Development and another part of each working group.
Likewise, the network seeks to “coordinate some cannabis projects and improve the training of researchers in each laboratory, through internships and stays in companies,” added the head of this project.
“Now we will be able to articulate ourselves in a network where we can work together between groups: a laboratory specialized in pharmacology, with a clinical group specialized in psychiatry, with a laboratory specialized in the extraction of natural products,” he specified.
With all this, they are looking to multiply the scope and depth of the project’s capabilities by a lot in the long run.
The CannaLatan network includes laboratories from the following universities:
In Mexico, the National Autonomous University of Mexico (UNAM); in Argentina, the University of Buenos Aires (UBA); in Spain, the University of Barcelona and the Complutense; in Brazil, the University of São Paulo; in Bolivia, the private University of Santa Cruz; in Costa Rica, the University of Costa Rica; and in Portugal, the University of Coimbra.
The exchange of knowledge between the regions will help move the sector forward
“Latin America has the advantage that there are countries that have already regulated the use of cannabis, while Spain has not,” he said, noting that in Uruguay, the fact that cannabis is legal facilitates collaboration with regulatory agencies.
According to the professor, the project is inspired by the experience of the Spanish Society for Research on Cannabinoids, which has a similar format but on a national scale. In his opinion, at present, cannabinoid research continues to face both the social taboo that exists with respect to cannabis and the lack of regulation for its medical use.
Finally, he added that “Without legislation we cannot move forward. We must have clear rules,” still having hopes for the future of cannabis.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in La Marihuana, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.